Related Experiment Video

Updated: May 5, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

E2F1 drives chemotherapeutic drug resistance via ABCG2

M T Rosenfeldt1, L A Bell1, J S Long1

  • 1Tumour Cell Death Laboratory, Cancer Research UK Beatson Institute, Glasgow, UK.

Oncogene
|November 27, 2013
PubMed

Insights

The transcription factor E2F1 directly activates ABCG2 transporter expression, a key driver of multidrug resistance in cancer. Inhibiting this E2F1-ABCG2 pathway can restore chemotherapy sensitivity and reduce tumor cell survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, often mediated by ATP-binding cassette (ABC) transporters.
  • Overexpression of ABC transporters in human cancers is linked to poor prognosis, but the genetic triggers for their expression remain largely unknown.

Purpose of the Study:

  • To investigate the genetic factors regulating ABCG2 transporter expression in cancer.
  • To elucidate the role of the transcription factor E2F1 in multidrug resistance.

Main Methods:

  • Analysis of E2F1 regulation of ABCG2 expression in various cell systems.
  • Correlation studies between E2F1 and ABCG2 levels in human lung cancer tissues.
  • In vitro and in vivo experiments assessing chemotherapeutic drug efflux and cell death.

Main Results:

  • The transcription factor E2F1 directly activates the expression of the major multidrug transporter ABCG2.
  • Elevated E2F1 and ABCG2 expression show a significant correlation in human lung cancers.
  • E2F1-mediated ABCG2 activity promotes chemotherapeutic drug efflux and suppresses chemotherapy-induced apoptosis, which can be reversed by ABCG2 inhibition.

Conclusions:

  • Identified a novel E2F1-ABCG2 signaling axis contributing to multidrug resistance in cancer.
  • Demonstrated a new function for E2F1 in regulating drug efflux and chemotherapy resistance.
  • This axis represents a potential therapeutic target for overcoming multidrug resistance in cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K